Medistim ASA/Nkr MEDI

1D1W1MYTD1Y5YMAX

About Medistim ASA

Medistim ASA is a Norwegian company specializing in the development and commercialization of medical devices used in cardiac, vascular, and transplant surgery. Its core business focuses on intraoperative blood flow measurement technology, notably through its proprietary products like the VeriQ and MiraQ systems. These systems are crucial for ensuring optimal blood flow during surgeries, thus helping to improve clinical outcomes. Founded in 1984, Medistim is headquartered in Oslo, Norway, and operates with a global network, distributing its products worldwide. The company's strategic strengths lie in its specialized focus on niche surgical applications and its continued innovation in medical technology.
Ticker
Nkr MEDI
Sector
Health
Primary listing
XOSL
Employees
159
Headquarters
Oslo, Norway
Website
www.medistim.com

Medistim ASA Metrics

BasicAdvanced
kr 4.6B
28.10
kr 9.04
1.01
kr 8.00
3.15%

Bulls say / Bears say

Recent trading shows strong demand and operating leverage. Q2 revenue rose 19.5% to NOK202m, own-product sales increased 33.6% on a currency-neutral basis, and EBIT rose 20.6% to NOK65.3m, giving a 32.3% margin. (Inderes)
The revenue base is becoming more dependable. Recurring sales were 67% of first-half revenue, while the company ended the period with NOK100.2m of cash after its dividend and no interest-bearing bank debt. (Inderes)
Medistim still has a sizeable expansion runway if adoption continues. Its latest presentation estimates a NOK7bn addressable market, says only about 10% is currently served, and puts penetration of US CABG procedures at roughly 40%. (Quartr, MarketScreener)
Growth is uneven outside Medistim’s own products: third-party distributor sales fell 7% in Q2 and 19.9% in the first half. That creates volatility and leaves more pressure on the company’s proprietary products to carry growth. (Inderes)
Profitability faces cost and mix risks. First-half gross margin fell to 80.9% from 82.5%, while US tariffs accounted for about NOK10m of material costs, even though EBIT margin remained strong. (MarketScreener, Exa)
Production capacity could become a constraint on growth. Medistim needs a semi-automated line for high-volume flow probes, but the project is technically complex and requires validation and regulatory approval before it can provide a longer-term solution. (Exa)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.

Medistim ASA Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Medistim ASA Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.